Alicia K. Morgans, MD, MPH, FASCO, on How Does Androgen Receptor Inhibition Affect Quality of Life?
2025 ASCO Annual Meeting
Alicia K. Morgans, MD, MPH, FASCO, of Dana-Farber Cancer Institute, discusses health-related quality-of-life data from the phase III ARANOTE trial, which evaluated the androgen receptor inhibitor darolutamide in combination with androgen-deprivation therapy (ADT) vs ADT plus placebo for patients with metastatic hormone-sensitive prostate cancer (Abstract 5004).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
On behalf of the ARASENS investigators, I was very pleased to present the ARASENS quality of life data. ARASENS is a phase three study in patients with metastatic hormone-sensitive prostate cancer. Patients were enrolled and were randomized to ADT plus darolutamide versus ADT and placebo to assess a primary endpoint of radiographic progression-free survival of darolutamide in this setting. Importantly, patients who were enrolled were predominantly high-volume metastatic disease and most had de novo metastatic hormone-sensitive disease. In terms of the quality of life analysis, patients were assessed by the Brief Pain. In the patients treated with ADT plus darolutamide versus ADT alone. I think also importantly the subscales of the FACT-P that were analyzed did suggest that certain subscales were improved more than others including urinary symptoms and prostate cancer-specific symptoms as well as functional well-being and social well-being, suggesting that patients were reporting that they had better time with their families and performing their daily activities. Ultimately, these suggest that darolutamide in the addition to ADT were improving metastatic hormone-sensitive prostate cancer patients' quality of life in addition to being associated with the radiographic progression-free survival advantage for this combination.
The ASCO Post Staff
Ruben A. Mesa, MD, of Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, presents results from a phase III trial investigating the efficacy of ropeginterferon alfa-2b vs anagrelide for the treatment of essential thrombocythemia (Abstract 6500).
The ASCO Post Staff
Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, IRCCS, University of Milano, discusses patient-reported outcomes from the phase III EMBER-3 trial, which investigated treatment with imlunestrant, investigator’s choice of standard endocrine therapy, or imlunestrant plus abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer (Abstract 1001).
The ASCO Post Staff
Nicholas D. James, PhD, FRCP, MBBS, of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, describes the use of a multimodal artificial intelligence (AI) model to identify benefit from second-generation androgen receptor pathway inhibitors in patients with high-risk nonmetastatic prostate cancer participating in the STAMPEDE trial (Abstract 5001).
The ASCO Post Staff
Praful Ravi, MBBChir, MRCP, of Dana-Farber Cancer Institute, presents findings from an ICECaP individual patient-data meta-analysis of randomized controlled trials on a treatment strategy used in high-risk localized prostate cancer (Abstract 5013).
The ASCO Post Staff
Frank A. Sinicrope, MD, of Mayo Clinic Rochester, reviews findings from the randomized Alliance A021502/ATOMIC trial, which studied standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III DNA mismatch repair–deficient (dMMR) colon cancer (LBA1).